The article reports on the delayed approval of the U.S. Food and Drug Administration (FDA) to the biosimilar drugs application. The generic industry urged FDA to develop a non-new drug application mechanism for generic biologics. The agency and the industry are arguing over the demonstration of science regarding the equivalency to present agents.